Status of Phase II H5N1 clinical trial Enrollment is ongoing and vaccination has commenced in the Company's phase II clinical trial with its H5N1 pandemc influenza vaccine. Interim results from this study are expected within three months. Financial Results Consolidated loss for the three-month period ended September 30, 2010 was $4,104,000 or $0.03 per basic and diluted share compared to a loss of $3,165,000 or $0.03 per basic and diluted share for the three-month period ended September 30, 2009. Since the beginning of the year the consolidated loss was $11,766,000 or $0.09 per basic and diluted share compared to a loss of $8,584,00 or $0.09 per basic and diluted share. Increase in the loss for the three and nine-month period is explained by the increase in R&D expenses in relation with the Phase II clinical trials that is underway.
Cash and cash equivalents were $14.7 million as at September 30, 2010.
As at November 12, 2010, there were 136,912,102 common shares issued and outstanding, 7,344,047 stock options outstanding, 3,796,982 unit options outstanding and 26,209,586 warrants outstanding.
Detailed financial statements and the MD&A are available at www.medicago.com or www.sedar.com.
Grant of stock options
Pursuant to terms and conditions of Medicago Inc.'s stock option plan, the company has granted 239,000 stock options to employees. The stock options were issued at an exercise price of 0.40 cents, will vest in three yearly instalments and are set to expire 10 years from the date of the grant.
Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against pandemic and seasonal influenza using a transient expression system which produces recombinant vaccine antigens in non-tr
|SOURCE Medicago Inc.|
Copyright©2010 PR Newswire.
All rights reserved